Form 4: NeueHealth CEO Awarded Significant Restricted Stock Units Following Shareholder Approval
SEC Form 4
George Lawrence Mikan III, CEO of NeueHealth, received 970,000 restricted stock units after shareholder approval of an amendment to the company's incentive plan.
Summary
- On May 2, 2024, NeueHealth CEO George Lawrence Mikan III was granted a total of 970,000 restricted stock units (RSUs).
- This grant is split into two tranches: 580,000 RSUs and 390,000 RSUs.
- The grant of 580,000 RSUs was initially approved on October 11, 2023, contingent on shareholder approval of an amendment to the company's Amended and Restated 2021 Omnibus Incentive Plan, which was obtained on May 2, 2024.
- These 580,000 RSUs will vest 100% on October 11, 2026.
- The grant of 390,000 RSUs was approved on March 11, 2024, also subject to the same shareholder approval obtained on May 2, 2024.
- These 390,000 RSUs will vest in three equal annual installments beginning on March 11, 2025.
- Each RSU represents a contingent right to receive one share of NeueHealth's common stock.
Sentiment
Score: 7
Explanation: The document indicates a positive development for the CEO and aligns his interests with shareholders through equity compensation. The vesting schedule promotes long-term commitment. However, the actual impact depends on the company's future performance.
Positives
- The grant of RSUs aligns the CEO's interests with those of the shareholders.
- The vesting schedules encourage long-term commitment from the CEO.
Future Outlook
The RSU grants are intended to incentivize the CEO's performance and align his interests with the long-term success of the company.
Industry Context
Equity compensation is a common practice in the healthcare industry to attract and retain top executive talent. The size and vesting schedule of the RSU grants are likely determined based on industry benchmarks and the company's performance goals.
Comparison to Industry Standards
- Comparing NeueHealth's executive compensation to similar healthcare companies like Oak Street Health (before its acquisition by CVS Health) or Alignment Healthcare would provide context on whether the RSU grants are in line with industry standards.
- Benchmarking against companies of similar market capitalization and growth stage is crucial for assessing the appropriateness of the compensation package.
- Factors such as company performance, revenue growth, and profitability are typically considered when determining executive compensation.
Stakeholder Impact
- Shareholders: The RSU grants aim to align the CEO's interests with shareholder value creation.
- Employees: The grants could have a positive impact on employee morale by demonstrating the company's commitment to leadership.
Key Dates
| Date | Description |
|---|---|
| October 11, 2023 | Initial approval of 580,000 RSU grant by the Compensation and Human Capital Committee, subject to shareholder approval. |
| March 11, 2024 | Approval of 390,000 RSU grant by the Compensation and Human Capital Committee as part of annual equity grants, subject to shareholder approval. |
| May 2, 2024 | Shareholder approval obtained for the amendment to the Issuer's Amended and Restated 2021 Omnibus Incentive Plan, satisfying the condition for the RSU grants. |
| May 2, 2024 | Date of transaction for both RSU grants. |
| March 11, 2025 | First vesting date for the 390,000 RSU grant (one-third vests). |
| October 11, 2026 | Vesting date for 100% of the 580,000 RSU grant. |
| May 06, 2024 | Date of filing of the SEC Form 4. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.